Shanghai Fosun Pharmaceutical (02196): Phase III clinical trial of FXS6837 capsules for the treatment of paroxysmal nocturnal hemoglobinuria initiated in China
Shanghai Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical Development Co., Ltd. (hereinafter referred to as the "Company"), a controlled subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the "Company"), has initiated a Phase III clinical trial in China for FXS6837 capsules (formerly project code: XH-S003, hereinafter referred to as "FXS6837") for the treatment of paroxysmal nocturnal hemoglobinuria.
Shanghai Fosun Pharmaceutical (02196) announced that recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "the Company"), through its controlled subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., initiated a Phase III clinical trial in China for FXS6837 capsules (formerly project code: XH-S003, hereinafter referred to as "FXS6837") for the treatment of paroxysmal nocturnal hemoglobinuria.
Related Articles
Jiangsu Broadcasting Cable Information Network Corporation (600959.SH) subsidiary intends to subscribe for shares in the Jiangsu Provincial Industrial M&A Fund for no more than RMB100 million.
PRU (02378) repurchased 420,400 shares on November 3 for GBP3.9518 million.
BANK OF GUIZHOU (06199): Cai Dong Resigns as Executive Director
Jiangsu Broadcasting Cable Information Network Corporation (600959.SH) subsidiary intends to subscribe for shares in the Jiangsu Provincial Industrial M&A Fund for no more than RMB100 million.
PRU (02378) repurchased 420,400 shares on November 3 for GBP3.9518 million.
BANK OF GUIZHOU (06199): Cai Dong Resigns as Executive Director
